These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 22017464

  • 1. Acute and subacute effects of EV iron sucrose on endothelial functions in hemodialysis patients.
    Ozkurt S, Ozenc F, Degirmenci NA, Temiz G, Musmul A, Sahin G, Yalcin AU.
    Ren Fail; 2012; 34(1):1-6. PubMed ID: 22017464
    [Abstract] [Full Text] [Related]

  • 2. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress.
    Swarnalatha G, Ram R, Neela P, Naidu MU, Dakshina Murty KV.
    Saudi J Kidney Dis Transpl; 2010 Sep; 21(5):852-8. PubMed ID: 20814119
    [Abstract] [Full Text] [Related]

  • 3. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C, Temiz A, Yeniçerioğlu Y, Calişkan S, Celik A, Sifil A, Onvural B, Camsari T.
    Scand J Urol Nephrol; 2003 Sep; 37(1):77-82. PubMed ID: 12745750
    [Abstract] [Full Text] [Related]

  • 4. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
    Pai AB, Norenberg J, Boyd A, Raj D, Chan LN.
    Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
    [Abstract] [Full Text] [Related]

  • 5. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
    Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, Grekas DM.
    Am J Nephrol; 2007 Dec; 27(6):572-9. PubMed ID: 17804904
    [Abstract] [Full Text] [Related]

  • 6. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Dec; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 7. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
    Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, Crespo R, Ramirez R, Aljama P.
    Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
    [Abstract] [Full Text] [Related]

  • 8. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
    Wu CJ, Lin HC, Lee KF, Chuang CK, Chen YC, Chen HH.
    Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
    [Abstract] [Full Text] [Related]

  • 9. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients.
    Bolaños L, González-Juanatey C, Testa A, Ranero R.
    Adv Perit Dial; 2008 Feb; 24():90-5. PubMed ID: 18986009
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
    Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N.
    Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
    [Abstract] [Full Text] [Related]

  • 11. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
    Kumbasar A, Gursu M, Kaya C, Ozturk S, Ergen A, Kemik A, Aydin Z, Uzun S, Karadag S, Kazancioglu R.
    J Nephrol; 2012 Jul; 25(5):825-32. PubMed ID: 22307439
    [Abstract] [Full Text] [Related]

  • 12. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
    Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A.
    Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
    [Abstract] [Full Text] [Related]

  • 13. Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis.
    Rangel EB, Espósito BP, Carneiro FD, Mallet AC, Matos AC, Andreoli MC, Guimarães-Souza NK, Santos BF.
    Ther Apher Dial; 2010 Apr; 14(2):186-92. PubMed ID: 20438541
    [Abstract] [Full Text] [Related]

  • 14. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
    Atalay H, Solak Y, Acar K, Govec N, Turk S.
    Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
    [Abstract] [Full Text] [Related]

  • 15. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 16. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.
    Am J Gastroenterol; 2005 Nov 23; 100(11):2503-9. PubMed ID: 16279906
    [Abstract] [Full Text] [Related]

  • 17. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
    Saglam F, Cavdar C, Uysal S, Cavdar Z, Camsari T.
    Ren Fail; 2007 Nov 23; 29(7):849-54. PubMed ID: 17994454
    [Abstract] [Full Text] [Related]

  • 18. Use of iron sucrose in dialysis patients sensitive to iron dextran.
    Haddad A, Abbadi R, Marji A.
    Saudi J Kidney Dis Transpl; 2009 Mar 23; 20(2):208-11. PubMed ID: 19237805
    [Abstract] [Full Text] [Related]

  • 19. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M, Hojs N, Premru V.
    Artif Organs; 2011 Jan 23; 35(1):63-8. PubMed ID: 20618233
    [Abstract] [Full Text] [Related]

  • 20. Differences between original intravenous iron sucrose and iron sucrose similar preparations.
    Toblli JE, Cao G, Oliveri L, Angerosa M.
    Arzneimittelforschung; 2009 Jan 23; 59(4):176-90. PubMed ID: 19517894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.